Pain Management & Opioids: Balancing Risks & Benefits - Updated (2.5 CME)

5 (2 votes)

The misuse of opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

From 1999 to 2016 more than 630,000 people died from drug overdoses.
115 Americans die every day from an opioid overdose.

The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018.

Edwin A. Salsitz

MD, DFASAM

Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.

Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids.

Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services. Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

Adam Gordon

MD, MPH, FACP, CMRO, DFASAM

Adam Gordon, MD MPH FACP DFASAM CMRO is the Elbert F. and Marie Christensen Endowed Research Professor of Medicine and Psychiatry at the University of Utah School of Medicine and Chief of Addiction Medicine at the Salt Lake City VA Healthcare System. He is a board certified internal medicine (American Board of Internal Medicine) and addiction medicine physician (American Board of Addiction Medicine) and has received distinction in both fields as a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). Prior to moving to Salt Lake City in the Winter of 2017, he was a Professor of Medicine and Clinical and Translational Sciences and an Advisory Dean in Student Affairs at the University of Pittsburgh School of Medicine. He maintains an active internal medicine – addiction medicine practice and has been honored nationally for his community service and clinical activities.

He has a 17-year track record of conducting clinical, health services, and implementation scienceresearch on the quality, equity, and efficiency of health care for vulnerable populations, including patients with opioid use and other substance disorders and/or who are homeless. Major themes of his current research include the identification and implementation of evidence-based care for patients with addiction disorders and understanding the intersection of pain syndromes, opioid misuse, and engagement into opioid use disorder treatment. He is a prior VA Health Services Research and Development Service Career Development Awardee. His research has been funded by the NIH, VA, AHRQ, PCORI, SAMHSA, among others. He has authored over 150 peer reviewed scientific papers, several books and book chapters, and hundreds of peer reviewed scholarly abstracts, presentations, and other work. He has been recognized with several national research awards for his research, including the Young Investigator of the Year from the Association for Medical Education and Research on Substance Abuse (AMERSA).

His professional career has been noted for service to federal government, community initiatives, and mentoring. For example, he directs the Buprenorphine Initiative in the VA where he leads a national consult service to increase the implementation of medication treatment for opioid use disorder. He is the Director of the National Coordinating Center for the VA Office of Academic Affiliations Advanced Interdisciplinary Fellowship in Addiction Research and Treatment, where he coordinates educational activities for fellowship sites across the country. He serves as the Editor-in-Chief of Substance Abuse, the Board of Directors of the International Society of Addiction Journal Editors, and the Board of Directors of AMERSA. He has had leading positions with several organizations including American Society of Addiction Medicine (ASAM. Chair of Continuing Medical Education), Allegheny County Medical Society (President, Board of Directors), and Pennsylvania Medical Society (Board of Trustees).

As a senior, tenured, faculty member, he is passionate about training the next generation of clinicians and clinical researchers. Apart from this advising of hundreds of medical students in his prior capacity as an Advisory Dean at the University of Pittsburgh, he has educated, trained, or mentored over 50 post-graduate scholars to be leaders in scholarly activities involving addiction treatment. His mentees have received research career development awards, large VA/NIH research grants, and local and national young investigator of the year awards. As a testament to his teaching and mentoring expertise, he was named as one of the inaugural VA Health Services Research and Development (HSR&D) National Mentor Network (MNet) mentors. In addition, he has received of research mentoring awards including from the University of Pittsburgh, the AMA, and AMERSA (2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award).

Adam lives with his wife, Margaret Conroy, MD MPH and children Lillian, Neil, and Martha in Salt Lake City, Utah. He enjoys gardening and tennis.

CME Information and Disclosure Listing

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

Name	Commercial Interest	What was received?	For what role?
Catherine R. Friedman, MD, FAPA, DFASAM, Chair	None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM	None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO	None
Zwaantje Hamming, FNP-C, CARN-AP	None
Noel Ilogu, MD, MRCP, DFASAM	None
Hebert L. Malinoff, MD, FACP, DFASAM	None
Edwin A. Salsitz, MD, DFASAM	None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE	None
Marcia Jackson PhD	None
Sandy Metcalfe	None

Program Planning Committee

Name	Commercial Interest	What was received?	For what role?
Herbert Malinoff, MD, FACP, DFASAM	None
Yngvild Olsen, MD, MPH	None
Theodore Parran, MD, FACP	None
Edwin Salsitz, MD, DFASAM	None
R. Corey Waller, MD, MS, FACEP	None

Faculty

Name	Commercial Interest	What was received?	For what role?
Edwin A. Salsitz, MD, DFASAM	None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO	None

ASAM CME Committee Reviewers

Name	Commercial Interest	What was received?	For what role?
Jacob Bobrowski, MD, FAAFP	None
Anthony H. Dekker, DO, DFASAM	None

ASAM Medical Education Council

Name	Commercial Interest	What was received?	For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair	Pfizer Johnson & Johnson Pfizer Canada	Grant funding Consulting Fees Consulting Fees	Principal Investigator Consulting Consulting
Daniel Alford, MD, MPH	None
Michael Fingerhood, MD, FACP, FASAM	None
Catherine R. Friedman, MD, FAPA, DFASAM	None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO	None
Miriam S. Komaromy, MD, FACP, DFASAM	None
Edwin A. Salsitz, MD, DFASAM	None
Mark P. Schwartz, MD, DFASAM	None
Mark A. Weiner, MD, FASAM	None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE	None
Marcia Jackson PhD	None
Jennifer L. Butchart	None
Penny S. Mills, MBA	None